Signal transduction pathways: The molecular basis for targeted therapies

被引:30
作者
Ethier, SP [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, Hlth Syst, Ann Arbor, MI 48109 USA
关键词
D O I
10.1053/srao.2002.34863
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The elucidation of the signal transduction pathways that regulate cell growth and differentiation has led to a number of exciting opportunities for novel cancer therapies. It is now well known that growth factors and cell matrix molecules activate cognate growth factor receptors and integrins, respectively, to initiate a complex signaling cascade that ultimately targets the nucleus, cell surface, and mitochondria. Signaling to these target molecules results in the regulation of gene transcription, cell adhesion and motility, and cell survival, all of which are integral parts of cellular growth control mechanisms. As a result of increased understanding of cell growth regulation mechanisms, a number of novel therapeutic agents have been developed and tested in preclinical models and, to some extent, in clinical trials. Based on our current understanding of growth regulation in normal and cancer cells, one would predict that these new agents could influence proliferation and survival of cancer cells, as well as their response to traditional cytotoxic therapies. In this overview, the mechanistic basis for the use of signal transduction-targeted novel therapeutics is presented, along with predictions regarding how they may interact with ionizing radiation in different subgroups of patients. Copyright 2002, Elsevier Science (USA). All rights reserved.
引用
收藏
页码:3 / 10
页数:8
相关论文
共 23 条
[1]   Blocking oncogenic Ras signaling for cancer therapy [J].
Adjei, AA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074
[2]   Growth factors and their receptors: New targets for prostate cancer therapy [J].
Barton, J ;
Blackledge, G ;
Wakeling, A .
UROLOGY, 2001, 58 (2A) :114-122
[3]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[4]   Farnesyltransferase inhibitors - Potential role in the treatment of cancer [J].
Cox, AD .
DRUGS, 2001, 61 (06) :723-732
[5]   FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition [J].
Cross, MJ ;
Claesson-Welsh, L .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) :201-207
[6]   Fibronectin, integrins, and growth control [J].
Danen, EHJ ;
Yamada, KM .
JOURNAL OF CELLULAR PHYSIOLOGY, 2001, 189 (01) :1-13
[7]   The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity [J].
Dent, P ;
Jarvis, WD ;
Birrer, MJ ;
Fisher, PB ;
Schmidt-Ullrich, RK ;
Grant, S .
LEUKEMIA, 1998, 12 (12) :1843-1850
[8]   Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? [J].
Fry, MJ .
BREAST CANCER RESEARCH, 2001, 3 (05) :304-312
[9]   The Type 1 growth factor receptors and their ligands considered as a complex system [J].
Gullick, WJ .
ENDOCRINE-RELATED CANCER, 2001, 8 (02) :75-82
[10]   The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions [J].
Han, DC ;
Shen, TL ;
Guan, JL .
ONCOGENE, 2001, 20 (44) :6315-6321